Mankal Medical Limited 10713311 false 2023-04-01 2024-03-31 2024-03-31 The principal activity of the company is general medical practice activities Digita Accounts Production Advanced 6.30.9574.0 true 10713311 2023-04-01 2024-03-31 10713311 2024-03-31 10713311 bus:OrdinaryShareClass1 2024-03-31 10713311 bus:OrdinaryShareClass2 2024-03-31 10713311 core:FinancialAssetsCostLessImpairment core:Non-currentFinancialInstruments 2024-03-31 10713311 core:CurrentFinancialInstruments 2024-03-31 10713311 core:CurrentFinancialInstruments core:WithinOneYear 2024-03-31 10713311 core:FurnitureFittingsToolsEquipment 2024-03-31 10713311 core:MotorVehicles 2024-03-31 10713311 bus:SmallEntities 2023-04-01 2024-03-31 10713311 bus:AuditExemptWithAccountantsReport 2023-04-01 2024-03-31 10713311 bus:FilletedAccounts 2023-04-01 2024-03-31 10713311 bus:SmallCompaniesRegimeForAccounts 2023-04-01 2024-03-31 10713311 bus:RegisteredOffice 2023-04-01 2024-03-31 10713311 bus:Director1 2023-04-01 2024-03-31 10713311 bus:Director2 2023-04-01 2024-03-31 10713311 bus:OrdinaryShareClass1 2023-04-01 2024-03-31 10713311 bus:OrdinaryShareClass2 2023-04-01 2024-03-31 10713311 bus:PrivateLimitedCompanyLtd 2023-04-01 2024-03-31 10713311 core:RetainedEarningsAccumulatedLosses 2023-04-01 2024-03-31 10713311 core:RevaluationReserve 2023-04-01 2024-03-31 10713311 core:FurnitureFittingsToolsEquipment 2023-04-01 2024-03-31 10713311 core:MotorCars 2023-04-01 2024-03-31 10713311 core:MotorVehicles 2023-04-01 2024-03-31 10713311 core:OfficeEquipment 2023-04-01 2024-03-31 10713311 core:KeyManagementPersonnel 2023-04-01 2024-03-31 10713311 core:KeyManagementPersonnelCloseFamilyMembersEntitiesUnderKeyManagementPersonnelsControl 2023-04-01 2024-03-31 10713311 countries:EnglandWales 2023-04-01 2024-03-31 10713311 2023-03-31 10713311 core:FurnitureFittingsToolsEquipment 2023-03-31 10713311 core:MotorVehicles 2023-03-31 10713311 2022-04-01 2023-03-31 10713311 2023-03-31 10713311 bus:OrdinaryShareClass1 2023-03-31 10713311 bus:OrdinaryShareClass2 2023-03-31 10713311 core:FinancialAssetsCostLessImpairment core:Non-currentFinancialInstruments 2023-03-31 10713311 core:CurrentFinancialInstruments 2023-03-31 10713311 core:CurrentFinancialInstruments core:WithinOneYear 2023-03-31 10713311 core:FurnitureFittingsToolsEquipment 2023-03-31 10713311 core:MotorVehicles 2023-03-31 iso4217:GBP xbrli:pure xbrli:shares

Registration number: 10713311

Mankal Medical Limited

Filleted Annual Report and Unaudited Abridged Financial Statements

for the Year Ended 31 March 2024

 

Mankal Medical Limited

Contents

Company Information

1

Abridged Balance Sheet

2 to 3

Notes to the Unaudited Abridged Financial Statements

4 to 7

 

Mankal Medical Limited

Company Information

Directors

Dr K Mankal

Dr S Mankal

Registered office

4 Great Oaks Park
Rogerstone
Newport
South Wales
NP10 9AT

Accountants

HSJ Accountants Ltd
Severn House
Hazell Drive
Newport
South Wales
NP10 8FY

 

Mankal Medical Limited

(Registration number: 10713311)
Abridged Balance Sheet as at 31 March 2024

Note

2024
£

2023
£

Fixed assets

 

Tangible assets

4

42,652

51,850

Other financial assets

5

54,223

47,433

 

96,875

99,283

Current assets

 

Debtors

425

469

Cash at bank and in hand

 

23,389

18,743

 

23,814

19,212

Prepayments and accrued income

 

798

780

Creditors: Amounts falling due within one year

(67,328)

(60,566)

Net current liabilities

 

(42,716)

(40,574)

Total assets less current liabilities

 

54,159

58,709

Accruals and deferred income

 

(1,260)

(1,194)

Net assets

 

52,899

57,515

Capital and reserves

 

Called up share capital

7

102

102

Revaluation reserve

4,722

(2,068)

Retained earnings

48,075

59,481

Shareholders' funds

 

52,899

57,515

 

Mankal Medical Limited

(Registration number: 10713311)
Abridged Balance Sheet as at 31 March 2024

For the financial year ending 31 March 2024 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Directors' responsibilities:

The members have not required the company to obtain an audit of its accounts for the year in question in accordance with section 476; and

The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These financial statements have been prepared in accordance with the special provisions relating to companies subject to the small companies regime within Part 15 of the Companies Act 2006.

All of the company’s members have consented to the preparation of an Abridged Balance Sheet in accordance with Section 444(2A) of the Companies Act 2006.

These financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime. As permitted by section 444 (5A) of the Companies Act 2006, the directors have not delivered to the registrar a copy of the Profit and Loss Account.

Approved and authorised by the Board on 19 November 2024 and signed on its behalf by:
 

.........................................

Dr K Mankal
Director

 

Mankal Medical Limited

Notes to the Unaudited Abridged Financial Statements for the Year Ended 31 March 2024

1

General information

The company is a private company limited by share capital, incorporated in England and Wales.

The address of its registered office is:
4 Great Oaks Park
Rogerstone
Newport
South Wales
NP10 9AT

These financial statements were authorised for issue by the Board on 19 November 2024.

2

Accounting policies

Summary of significant accounting policies and key accounting estimates

The principal accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.

Statement of compliance

These abridged financial statements have been prepared in accordance with Financial Reporting Standard 102 Section 1A smaller entities - 'The Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland' and the Companies Act 2006 (as applicable to companies subject to the small companies' regime).

Basis of preparation

These abridged financial statements have been prepared using the historical cost convention except that as disclosed in the accounting policies certain items are shown at fair value.

Revenue recognition

Turnover comprises the fair value of the consideration received or receivable for the sale of goods and provision of services in the ordinary course of the company’s activities. Turnover is shown net of value added tax, returns, rebates and discounts.

The company recognises revenue when:
The amount of revenue can be reliably measured;
it is probable that future economic benefits will flow to the entity;
and specific criteria have been met for each of the company's activities.

Tangible assets

Tangible assets are stated in the balance sheet at cost, less any subsequent accumulated depreciation and subsequent accumulated impairment losses.

The cost of tangible assets includes directly attributable incremental costs incurred in their acquisition and installation.

Depreciation

Depreciation is charged so as to write off the cost of assets, other than land and properties under construction over their estimated useful lives, as follows:

 

Mankal Medical Limited

Notes to the Unaudited Abridged Financial Statements for the Year Ended 31 March 2024

Asset class

Depreciation method and rate

Office equipment

20% straight line

Motor Vehicle

20% straight line

Cash and cash equivalents

Cash and cash equivalents comprise cash on hand and call deposits, and other short-term highly liquid investments that are readily convertible to a known amount of cash and are subject to an insignificant risk of change in value.

Trade debtors

Trade debtors are amounts due from customers for merchandise sold or services performed in the ordinary course of business.

Trade debtors are recognised initially at the transaction price. They are subsequently measured at amortised cost using the effective interest method, less provision for impairment. A provision for the impairment of trade debtors is established when there is objective evidence that the company will not be able to collect all amounts due according to the original terms of the receivables.

Trade creditors

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Accounts payable are classified as current liabilities if the company does not have an unconditional right, at the end of the reporting period, to defer settlement of the creditor for at least twelve months after the reporting date. If there is an unconditional right to defer settlement for at least twelve months after the reporting date, they are presented as non-current liabilities.

Trade creditors are recognised initially at the transaction price and subsequently measured at amortised cost using the effective interest method.

Borrowings

Interest-bearing borrowings are initially recorded at fair value, net of transaction costs. Interest-bearing borrowings are subsequently carried at amortised cost, with the difference between the proceeds, net of transaction costs, and the amount due on redemption being recognised as a charge to the profit and loss account over the period of the relevant borrowing.

Interest expense is recognised on the basis of the effective interest method and is included in interest payable and similar charges.

Borrowings are classified as current liabilities unless the company has an unconditional right to defer settlement of the liability for at least twelve months after the reporting date.

Share capital

Ordinary shares are classified as equity. Equity instruments are measured at the fair value of the cash or other resources received or receivable, net of the direct costs of issuing the equity instruments. If payment is deferred and the time value of money is material, the initial measurement is on a present value basis.

Dividends

Dividend distribution to the company’s shareholders is recognised as a liability in the financial statements in the reporting period in which the dividends are declared.

 

Mankal Medical Limited

Notes to the Unaudited Abridged Financial Statements for the Year Ended 31 March 2024

3

Staff numbers

The average number of persons employed by the company (including directors) during the year, was 2 (2023 - 2).

4

Tangible assets

Office equipment
 £

Motor vehicles
 £

Total
£

Cost or valuation

At 1 April 2023

4,378

49,870

54,248

Additions

1,577

-

1,577

At 31 March 2024

5,955

49,870

55,825

Depreciation

At 1 April 2023

1,567

831

2,398

Charge for the year

801

9,974

10,775

At 31 March 2024

2,368

10,805

13,173

Carrying amount

At 31 March 2024

3,587

39,065

42,652

At 31 March 2023

2,811

49,039

51,850

 

Mankal Medical Limited

Notes to the Unaudited Abridged Financial Statements for the Year Ended 31 March 2024

5

Other financial assets (current and non-current)

2024
£

2023
£

Non-current financial assets

Financial assets at cost less impairment

54,223

47,433

6

Reserves

The changes to each component of equity resulting from items of other comprehensive income for the current year were as follows:

Revaluation reserve
£

Retained earnings
£

Surplus/deficit on revaluation of other assets

6,790

(6,790)

7

Share capital

Allotted, called up and fully paid shares

 

2024

2023

 

No.

£

No.

£

Ordinary Shares of £1 each

100

100

100

100

Ordinary B Shares of £1 each

2

2

2

2

 

102

102

102

102

8

Related party transactions

Key management personnel

Director

Summary of transactions with key management

During the year the directors made unsecured, interest free, repayable on demand loans to the company. At the balance sheet date, the company owed the directors £68,031 (2023 - £60,374).